In addition, in patients with idiopathic pulmonary fibrosis (IPF), the level of circulating legumain is suggested as one of the six biomarkers in an IPF clinical decision index, since legumain is involved in promoting disease progression [119]. This evidence concerns the gene LGMN and pulmonary fibrosis.